Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New study pursues the impact of pregnancy on drug efficacy

28.11.2002


Drs. Vadivel Ganapathy (left) and Puttur D. Prasad are part of National Institutes of Health Program Project grant looking at whether pregnant women should continue to take many common medications at the same dose as before pregnancy.


The human placenta (pictured left and schematic description on the right) ensures that baby gets proper nutrients and oxygen but it may also interfere with the blood levels of some common medications that women continue to take during pregnancy.

Click here for full size image


Whether pregnant women with conditions ranging from ulcers to AIDS should keep taking the same doses of medicine they took before pregnancy is a question Medical College of Georgia researchers want answered.

They are betting they’ll find that to maintain efficacy, pregnant women will need higher doses and that the placenta, a 2-pound temporary organ of pregnancy, is why.

"The idea that we are developing is that pregnant women are so different from non-pregnant women in terms of drug handling," said Dr. Vadivel Ganapathy, biochemist and interim chairman of the MCG Department of Biochemistry and Molecular Biology. "In non-pregnant women, only the intestine, liver and kidney are important to drug handling."



But the placenta – where mother and fetus connect and the fetus’ source of nutrients and oxygen – also can metabolize many drugs so they no longer function as drugs or it can transport drugs directly to the fetus.

"Normally the placenta is believed to be a barrier, a protective mechanism for the baby, so if the mother’s blood contains some drugs, the placenta is believed not to let it go the fetus. But that is not true for all drugs," said Dr. Ganapathy, who has studied the placenta’s interactions with everything from street drugs to folic acid.

He has cloned a transport system expressed in high levels in the placenta – called an organic cation transporter, or OCT3, because it can handle a broad spectrum of therapeutic drugs that contain a positive charge. "We are still trying to figure out the physiological role of this transporter, but we know it transports a lot of drugs," he said.

Now, as part of a National Institutes of Health Program Project grant at the University of Washington at Seattle, he is using the drug-handling capacity of this transporter to study the impact of pregnancy on drug efficacy. He’ll be looking at how the transporter impacts drugs levels in animal models as well as human placental cells in culture.

"We ought to know more about the placenta, what it does in terms of drugs, before we give the same dosage, the same regimen to pregnant women that we give to non-pregnant women," Dr. Ganapathy said.

As an example, the common anti-ulcer medication, cimetidine, known by the trade name Tagamet, readily interacts with the cation transporter. He’s using that drug to learn how much the drug level in the blood is affected by pregnancy. "A lower blood level may be innocuous with cimetidine, but what if you are treating a patient who has AIDS with anti-viral drugs?" Dr. Ganapathy said. "In a non-pregnant state, this particular anti-viral drug at a given dose is very good at keeping the level of HIV low in the blood. Now, if that HIV patient is pregnant and you give the same drug at the same dosage, that might not be enough to keep the viral load low. The viral load increases in the mother’s blood which also increases the chance of passing it through the placenta and on to the baby."

Animal studies examining a drug’s impact on a developing fetus are routinely done as part of drug development and Dr. Ganapathy will be doing that as part of his study, too. These fetal studies sometimes show that medications can’t be taken during pregnancy at any dose.

But studies on the impact on drug efficacy for the mothers-to-be have not been pursued, Dr. Ganapathy said, and dosages typically are not altered for those women.

This issue is central to the five-year study at MCG and the University of Washington, which was recently established as one of 11 new Specialized Centers of Research on Sex and Gender Factors by the NIH.

"We will look at the organic cation transporter, or OCT3, which is expressed primarily in the placenta and handles a lot of drugs, as a way to characterize the drugs normally used in pregnant women which can be handled by this transporter," Dr. Ganapathy said of his $1.5 million grant. "These drugs should be flagged saying the efficacy of the drug may be altered during pregnancy because you have this transporter sitting there during pregnancy which can transport these drugs, take it away from the mother and put it into the baby." Dr. Puttur D. Prasad, researcher in the MCG Department of Obstetrics and Gynecology, is a co-investigator on Dr. Ganapathy’s study.

Related studies at the University of Washington will use non-therapeutic doses of common, non-toxic drugs to see if blood levels vary in pregnant versus non-pregnant women and primates.

Toni Baker | EurekAlert!
Further information:
http://www.mcg.edu/

More articles from Health and Medicine:

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Scientist invents way to trigger artificial photosynthesis to clean air

26.04.2017 | Materials Sciences

Ammonium nitrogen input increases the synthesis of anticarcinogenic compounds in broccoli

26.04.2017 | Agricultural and Forestry Science

SwRI-led team discovers lull in Mars' giant impact history

26.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>